AbbVie's new hope Skyrizi bests Novartis' Cosentyx at clearing patients' skin

Skyrizi could hit $1 billion in sales by 2021, according to UBS analyst Navin Jacob. (AbbVie)

AbbVie is placing high hopes in its next-gen psoriasis med Skyrizi as it looks for business drivers in the post-Humira, post-Allergan merger landscape. With sales already ahead of consensus, AbbVie is now touting competitor topping data that could give Skyrizi an even bigger leg up. 

After 52 weeks, Skyrizi beat out Novartis' Cosentyx at clearing patients' skin by 90% over baseline, according to phase 3 trial data released Tuesday. 

Eighty-seven percent of patients treated with Skyrizi saw their skin clear by at least 90% at the 52-week mark, compared with 57% of patients on Cosentyx, AbbVie said. At the 16-week mark, Skyrizi matched up to Cosentyx with 74% of patients seeing 90% clearer skin compared with 66% on Cosentyx. 

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

"Head-to-head data like these are crucial to helping patients and their doctors make informed treatment decisions," said Michael Severino, AbbVie president.

RELATED: AbbVie's new launches Skyrizi, Rinvoq aren't getting enough credit: analyst

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.